Effect of Xinling Wan in treatment of stable angina pectoris: a randomized, double-blinded, placebo parallel-controlled, multicenter trial.
10.19540/j.cnki.cjcmm.20171226.002
- Author:
Jian-Wei GAO
1
;
Xue-Min GAO
2
;
Ting ZOU
3
;
Tian-Meng ZHAO
3
;
Dong-Hua WANG
3
;
Zong-Gui WU
4
;
Chang-Jie REN
5
;
Xing WANG
6
;
Nai-Zhi GENG
7
;
Ming-Jun ZHAO
8
;
Qiu-Ming LIANG
9
;
Xing FENG
10
;
Bai-Song YANG
11
;
Jun-Ling SHI
12
;
Qi HUA
13
Author Information
1. Beijing Institute of Heart, Lung and Blood Vessel Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
2. Professional Committee of Pharmaceutical Research and Clinical Evaluation, China Association of Traditional Chinese Medicine, Beijing 100101, China.
3. Beijing COMPETE Pharmaceutical Research and Clinical Evaluation Center, Beijing 100101, China.
4. Shanghai Changzheng Hospital, Shanghai 200003, China.
5. Jining First People's Hospital, Jining 272011, China.
6. Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin 150001, China.
7. First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin 150040, China.
8. Affiliated Hospital of Shaanxi College of Chinese Medicine, Xianyang 712000, China.
9. Qinzhou Hospital of Traditional Chinese Medicine, Qinzhou 535000, China.
10. The People's Hospital of Jilin, Jilin 132000, China.
11. China People's Liberation Army 463 Hospital, Shenyang 110042, China.
12. Tangshan Hospital of Chinese Medicine, Tangshan 063000, China.
13. Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
- Publication Type:Journal Article
- Keywords:
Xinling Wan;
clinical trial;
coronary heart disease;
effectiveness;
safety;
stable angina pectoris
- From:
China Journal of Chinese Materia Medica
2018;43(6):1268-1275
- CountryChina
- Language:Chinese
-
Abstract:
To evaluate the effectiveness and safety of Xinling Wan on patients with stable angina pectoris, a randomized, double-blinded, placebo parallel-controlled, multicenter clinical trial was conducted. A total of 232 subjects were enrolled and randomly divided into experiment group and placebo group. The experiment group was treated with Xinling Wan (two pills each time, three times daily) for 4 weeks, and the placebo group was treated with placebo. The effectiveness evaluation showed that Xinling Wan could significantly increase the total duration of treadmill exercise among patients with stable angina pectoris. FAS analysis showed that the difference value of the total exercise duration was between experiment group (72.11±139.32) s and placebo group (31.25±108.32) s. Xinling Wan could remarkably increase the total effective rate of angina pectoris symptom score, and the analysis showed that the total effective rate was 78.95% in experiment group and 42.61% in placebo group. The reduction of nitroglycerin dose was (2.45±2.41) tablets in experiment group and (0.50±2.24) tablets in placebo group on the basis of FAS analysis. The decrease of symptom integral was (4.68±3.49) in experiment group and (3.19±3.31) in placebo group based on FAS analysis. Besides, Xinling Wan could decrease the weekly attack time and the duration of angina pectoris. PPS analysis results were similar to those of FAS analysis. In conclusion, Xinling Wan has an obvious therapeutic effect in treating stable angina pectoris, with a good safety and a low incidence of adverse event and adverse reaction in experiment group.
